Related Experiment Video
Updated: Aug 20, 2026

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI
Published on: April 18, 2011
[Additional effect of SERM: central nervous system]
1Department of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science.
Abstract:
Raloxifene is a selective estrogen-receptor modulator recently launched in Japan as a new medicine for treatment of postmenopausal osteoporosis. Raloxifene stimulates neurite outgrowth in cultured cells and increases hippocampal cholineacethyl trasferase activity and serotonin receptor in the brain of ovariectomized rats. As a part of the Multiple Outcomes of Raloxifene Evaluation trial, 7,478 postmenopausal women with osteoporosis were studied by using six tests of cognitive function. There was some evidence that Raloxifene may lower the risk of a decline in memory and attention. It is expected that novel SERM, which has more specific efficacy improving cognitive function will be developed.
Related Concept Videos
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic drugs,...
Sympathetic Activation
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Parasympathetic Signaling
The effects of...
Skeletal Muscle Relaxants: Adverse Effects
Unlike...